Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AILT
MCID: ANG046
MIFTS: 52

Angioimmunoblastic T-Cell Lymphoma (AILT)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

About this section

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 52 58 54 15 17 32
Immunoblastic Lymphadenopathy 52 58 43 17
T-Cell Lymphoma, Aild Type 52 58
Lymphogranulomatosis X 52 58
Angioimmunoblastic Lymphadenopathy 71
Aitl 52
Ailt 58

Characteristics:

Orphanet epidemiological data:

58
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0111147
MeSH 43 D007119
NCIt 49 C7528
SNOMED-CT 67 835009
ICD10 32 C86.5
ICD10 via Orphanet 33 C86.5
UMLS via Orphanet 72 C0020981
Orphanet 58 ORPHA86886
UMLS 71 C0020981
Sources

Summaries for Angioimmunoblastic T-Cell Lymphoma

About this section
Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to peripheral t-cell lymphoma and lymphoma, hodgkin, classic, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is CXCL13 (C-X-C Motif Chemokine Ligand 13), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Wikipedia : 74 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Sources

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

About this section

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 275)
# Related Disease Score Top Affiliating Genes
1 peripheral t-cell lymphoma 31.8 TNFRSF8 TIA1 TET2 SYK RHOA PDCD1
2 lymphoma, hodgkin, classic 31.4 TNFRSF8 TIA1 GZMB BCL6
3 b-cell lymphoma 31.2 TNFRSF8 TIA1 SYK MME CXCL13 BCL6
4 marginal zone b-cell lymphoma 31.2 TNFRSF8 MME BCL6
5 anaplastic large cell lymphoma 31.1 TNFRSF8 TIA1 GZMB
6 lymphoma 31.1 TNFRSF8 TIA1 RHOA PDCD1 MME ITK
7 t-cell lymphoma, subcutaneous panniculitis-like 30.9 TNFRSF8 TIA1 GZMB
8 nodular lymphocyte predominant hodgkin lymphoma 30.9 TNFRSF8 PDCD1 BCL6
9 panniculitis 30.8 TNFRSF8 TIA1 GZMB
10 primary cutaneous t-cell lymphoma 30.8 TNFRSF8 PDCD1
11 diffuse large b-cell lymphoma 30.7 VEGFA TNFRSF8 SYK PDCD1 MME BCL6
12 mycosis fungoides 30.7 TNFRSF8 TIA1 GZMB CD28
13 hepatosplenic t-cell lymphoma 30.7 TIA1 GZMB
14 lymphoblastic lymphoma 30.6 TNFRSF8 MME BCL6
15 composite lymphoma 30.5 TNFRSF8 TIA1 MME GZMB BCL6
16 castleman disease 30.4 VEGFA CXCL13 BCL6
17 plasma cell neoplasm 30.2 VEGFA TNFRSF8 MME BCL6
18 burkitt lymphoma 30.2 VAV1 TNFRSF8 MME CXCL13 BCL6
19 mantle cell lymphoma 30.1 VEGFA SYK MME BCL6
20 lymphoma, non-hodgkin, familial 30.0 VEGFA TNFRSF8 TIA1 SYK MME GZMB
21 hematologic cancer 30.0 VEGFA TNFRSF8 SYK MME BCL6
22 leukemia, chronic lymphocytic 29.8 VEGFA TNFRSF8 SYK MME CD28 BCL6
23 myelodysplastic syndrome 29.3 VEGFA TET2 PDCD1 IDH2 GZMB
24 myeloma, multiple 29.2 VEGFA TNFRSF8 MME MAF IDH2 CD28
25 leukemia, acute myeloid 29.2 VEGFA VAV1 TNFRSF8 TET2 SYK MME
26 systemic lupus erythematosus 28.9 VEGFA TBX21 SYK PDCD1 ICOS CXCL13
27 exanthem 10.8
28 splenomegaly 10.7
29 lymphoproliferative syndrome 10.7
30 polyclonal hypergammaglobulinemia 10.7
31 hemolytic anemia 10.7
32 thrombocytopenia 10.6
33 ureteral lymphoma 10.6 MME BCL6
34 bladder lymphoma 10.5 MME BCL6
35 prostate lymphoma 10.5 MME BCL6
36 epiglottis neoplasm 10.5 MME BCL6
37 anemia, autoimmune hemolytic 10.5
38 hypereosinophilic syndrome 10.5
39 heart lymphoma 10.5 MME BCL6
40 ovarian lymphoma 10.5 MME BCL6
41 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.5 TNFRSF8 BCL6
42 autoimmune disease 10.5
43 liver lymphoma 10.5 MME BCL6
44 colon lymphoma 10.5 MME BCL6
45 intravascular large b-cell lymphoma 10.5 MME BCL6
46 follicular lymphoma 10.5
47 purpura 10.5
48 eye lymphoma 10.5 CXCL13 BCL6
49 lymphomatoid granulomatosis 10.4 TIA1 GZMB
50 gastric lymphoma 10.4 MME CXCL13 BCL6

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma
Sources

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

About this section

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 BCL6 CD28 CXCL13 ICOS ITK PDCD1
2 endocrine/exocrine gland MP:0005379 10.25 BCL6 CD28 ICOS ITK PDCD1 PDCD1LG2
3 immune system MP:0005387 10.25 BCL6 CD28 CXCL13 ICOS ITK MAF
4 cellular MP:0005384 10.23 BCL6 CD28 CXCL13 ITK MME PDCD1
5 homeostasis/metabolism MP:0005376 10.18 BCL6 CD28 ICOS MAF MME PDCD1
6 neoplasm MP:0002006 9.81 CD28 ICOS IDH2 PDCD1 PDCD1LG2 RC3H1
7 liver/biliary system MP:0005370 9.8 BCL6 MME PDCD1 RC3H1 SYK TET2
8 no phenotypic analysis MP:0003012 9.5 BCL6 ICOS PDCD1LG2 RC3H1 SYK TET2
9 renal/urinary system MP:0005367 9.17 MAF PDCD1 RC3H1 RHOA SYK TET2
Sources

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

About this section

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 303)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4 95058-81-4 60750
2
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Pirarubicin Investigational Phase 4 72496-41-4
6 HIV Protease Inhibitors Phase 4
7
protease inhibitors Phase 4
8
asparaginase Phase 4
9 BB 1101 Phase 4
10 Orange Approved Phase 3
11
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
12
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
15
Dalteparin Approved Phase 3 9005-49-6
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
22
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
23
Romidepsin Approved, Investigational Phase 3 128517-07-7 5352062
24
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
25
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
26 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
28 Anesthetics, Dissociative Phase 3
29 Gastrointestinal Agents Phase 3
30 Antiemetics Phase 3
31 Autonomic Agents Phase 3
32 Analgesics Phase 3
33 Central Nervous System Depressants Phase 3
34 Hematinics Phase 3
35 Cola Phase 3
36 Antipsychotic Agents Phase 3
37 Tranquilizing Agents Phase 3
38 Analgesics, Opioid Phase 3
39 Neurotransmitter Agents Phase 3
40 Psychotropic Drugs Phase 3
41 Antipruritics Phase 3
42 Anti-Anxiety Agents Phase 3
43 Serotonin Agents Phase 3
44 Serotonin Antagonists Phase 3
45 Liver Extracts Phase 3
46 Epoetin alfa Phase 3 113427-24-0
47 Heparin, Low-Molecular-Weight Phase 3
48 Narcotics Phase 3
49 Excitatory Amino Acid Antagonists Phase 3
50 Excitatory Amino Acids Phase 3

Interventional clinical trials:

(show top 50) (show all 266)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
3 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
4 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
5 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
10 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
11 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
12 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
13 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
14 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
15 A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
16 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
17 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
18 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
19 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
20 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
21 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
22 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
23 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
25 Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
26 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
27 Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial Unknown status NCT03273452 Phase 2 Chidamide
28 Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
29 An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Unknown status NCT02464228 Phase 2 Tipifarnib
30 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
31 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
32 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
33 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
34 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Unknown status NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
35 Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
36 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
37 A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
38 STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) Completed NCT01553786 Phase 2 Lenalidomide
39 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
40 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
41 A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial Completed NCT02424045 Phase 2 BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
42 Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
43 Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma Completed NCT00436618 Phase 2 Everolimus
44 Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
45 A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
46 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
47 Diffuse Large B Cell And Peripheral T-Cell Non-Hodgkin's Lymphoma In The Frail Elderly. Progressive And Cautious Treatment Strategy In Poor Status Patients. A Phase II Trial With Emphasis On Geriatric Assessment And Quality Of Life Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate
48 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
49 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
50 Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Cochrane evidence based reviews: immunoblastic lymphadenopathy

Sources

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

About this section
Sources

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

About this section

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

40
T Cells, B Cells, Bone, Bone Marrow, Lymph Node, Nk Cells, Liver
Sources

Publications for Angioimmunoblastic T-Cell Lymphoma

About this section

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 1127)
# Title Authors PMID Year
1
Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. 54 61
18792075 2008
2
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 54 61
16680156 2006
3
Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. 54 61
16625095 2006
4
CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. 54 61
16084948 2005
5
Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene. 54 61
15370207 2004
6
Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: A case report with literature review. 61
31482600 2020
7
Leukaemic relapse of angioimmunoblastic T-cell lymphoma. 61
32037513 2020
8
Update on peripheral T-cell lymphomas with T-helper phenotype:  Are there too many subtypes? 61
31870687 2020
9
Approach to nodal-based T-cell lymphomas. 61
31785821 2020
10
Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review. 61
31978091 2020
11
Neoantigen-activated haploidentical T cell therapy for angioimmunoblastic T-cell lymphoma. 61
31689517 2020
12
EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma. 61
31793218 2020
13
High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center. 61
31892973 2020
14
Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype. 61
31870198 2019
15
Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. 61
31859368 2019
16
Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission. 61
31204875 2019
17
Epstein-Barr virus infection or malignant lymphoma - what you see is not what you get. 61
31880273 2019
18
Epstein-Barr Virus-Induced Cutaneous Diffuse Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma. 61
31599749 2019
19
Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. 61
31393197 2019
20
The life and death of the germinal center. 61
31751845 2019
21
Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma. 61
31908892 2019
22
3D analysis of morphological alterations of the fibroblastic reticular cells in reactive and neoplastic human lymph nodes. 61
31285059 2019
23
RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment. 61
31394087 2019
24
Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr virus positivity and its effects on clinicopathologic features. 61
30240776 2019
25
Acquired Angioedema: A Rare Manifestation of Angioimmunoblastic T Cell Lymphoma. 61
31741940 2019
26
[Angioimmunoblastic T-cell lymphoma: histopathological grading and prognosis]. 61
31594043 2019
27
Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma? 61
31634059 2019
28
Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases. 61
30809041 2019
29
Metronidazole-induced encephalopathy during treatment for refractory diarrhea after cord blood transplantation. 61
30835083 2019
30
Multistaining Optimization for Epstein-Barr Virus-Encoded RNA In Situ Hybridization and Immunohistochemistry of Formalin-Fixed Paraffin-Embedded Tissues Using an Automated Immunostainer. 61
31455058 2019
31
GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism. 61
31447347 2019
32
Bone Marrow Infiltration of Angioimmunoblastic T-Cell Lymphoma. 61
31556696 2019
33
Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. 61
30980412 2019
34
Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype. 61
31283630 2019
35
Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma. 61
31423206 2019
36
Angioimmunoblastic T-cell lymphoma mimicking drug fever and infectious etiology after a thyroidectomy: A case report. 61
31441883 2019
37
A case of an insect bite-like reaction in a patient with angioimmunoblastic T-cell lymphoma. 61
31456577 2019
38
Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma. 61
30648445 2019
39
Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. 61
30985955 2019
40
Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. 61
30952973 2019
41
Cutaneous manifestations of angioimmunoblastic T-cell lymphoma. 61
31450279 2019
42
High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. 61
31292228 2019
43
A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification. 61
29629950 2019
44
The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. 61
30952970 2019
45
Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation. 61
30732495 2019
46
Monoclonal plasma cell infiltrates in the setting of cutaneous follicular helper T cell lymphoproliferative disorders. 61
31077877 2019
47
Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. 61
30557716 2019
48
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. 61
30914464 2019
49
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. 61
30694529 2019
50
Deregulated expression of NKL homeobox genes in T-cell lymphomas. 61
31143370 2019
Sources

Variations for Angioimmunoblastic T-Cell Lymphoma

About this section

Cosmic variations for Angioimmunoblastic T-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM108378711 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,angioimmunoblastic T cell lymphoma c.50G>T p.G17V 3:49375540-49375540 0
Sources

Expression for Angioimmunoblastic T-Cell Lymphoma

About this section
Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.
Sources

Pathways for Angioimmunoblastic T-Cell Lymphoma

About this section

Pathways related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.88 VEGFA VAV1 TNFRSF8 SYK RHOA PDCD1LG2
2
Akt Signaling 63
Show member pathways
 13.27 VAV1 TNFRSF8 SYK RHOA ITK CXCL13
3
Allograft rejection 1 36
Show member pathways
 12.7 VEGFA ICOS GZMB CXCL13 CD28
4
Immune response NFAT in immune response 22
Show member pathways
 12.48 VAV1 SYK ITK ICOS CD28
5
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.42 VEGFA VAV1 SYK ITK BCL6
6
T cell receptor signaling pathway 36
Show member pathways
 12.34 VAV1 RHOA PDCD1 ITK ICOS CD28
7
RhoGDI Pathway 63
Show member pathways
 12.18 VEGFA VAV1 SYK RHOA GZMB
8
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.17 VAV1 SYK CD28 BCL6
9
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.15 VAV1 SYK ITK ICOS CD28
10
Cell adhesion molecules (CAMs) 36
11.95 PDCD1LG2 PDCD1 ICOS CD28
11
CD28 co-stimulation 65
Show member pathways
 11.89 VAV1 PDCD1LG2 PDCD1 ICOS CD28
12
NF-kappaB Signaling 4
11.84 TNFRSF8 TBX21 SYK PDCD1LG2 PDCD1 ITK
13
Translocation of ZAP-70 to Immunological synapse 65
Show member pathways
 11.81 PDCD1LG2 PDCD1 ITK
14
TCR signaling in naive CD4+ T cells 1
Show member pathways
 11.8 VAV1 ITK CD28
15
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers 65
Show member pathways
 11.79 VAV1 SYK ITK
16
Innate Lymphoid Cell Differentiation Pathways 64
11.63 TBX21 ICOS GZMB
17
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions 64
11.32 TNFRSF8 PDCD1LG2 PDCD1 ICOS CD28
18
Class I PI3K signaling events 1
11.25 VAV1 RHOA ITK
19
T-Cell Receptor and Co-stimulatory Signaling 1
11.1 PDCD1 ITK CD28
20
B Cell Development Pathways 64
11.08 TNFRSF8 PDCD1 MME ICOS BCL6
21
Regulation of signaling by CBL 65
10.86 VAV1 SYK
22
Cytosine methylation 1
Show member pathways
 10.68 TET2 IDH2
Sources

GO Terms for Angioimmunoblastic T-Cell Lymphoma

About this section

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 VAV1 PDCD1LG2 ICOS CXCL13 CD28
2 cell surface receptor signaling pathway GO:0007166 9.84 SYK PDCD1LG2 CXCL13 CD28
3 immune system process GO:0002376 9.8 SYK PDCD1LG2 PDCD1 ITK CD28 BCL6
4 neutrophil chemotaxis GO:0030593 9.73 VAV1 SYK CXCL13
5 regulation of T cell proliferation GO:0042129 9.58 RC3H1 CD28
6 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.58 VEGFA VAV1 RHOA
7 negative regulation of activated T cell proliferation GO:0046007 9.57 RC3H1 PDCD1LG2
8 positive regulation of cell adhesion GO:0045785 9.54 VEGFA VAV1 RHOA
9 positive regulation of cellular component movement GO:0051272 9.52 VEGFA BCL6
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.51 TBX21 CD28
11 positive regulation of alpha-beta T cell differentiation GO:0046638 9.49 SYK RHOA
12 positive regulation of alpha-beta T cell proliferation GO:0046641 9.48 SYK CD28
13 negative regulation of T-helper 17 cell differentiation GO:2000320 9.46 TBX21 RC3H1
14 germinal center formation GO:0002467 9.43 CXCL13 BCL6
15 T cell activation GO:0042110 9.43 VAV1 ITK CD28
16 regulation of germinal center formation GO:0002634 9.16 RC3H1 BCL6
17 T cell costimulation GO:0031295 9.02 VAV1 PDCD1LG2 PDCD1 ICOS CD28
18 beta selection GO:0043366 8.96 SYK RHOA

Molecular functions related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 VEGFA VAV1 TNFRSF8 TIA1 TET2 TBX21
Sources

Sources for Angioimmunoblastic T-Cell Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....